Clicky

Arovella Therapeutics Limited(ALA)

Description: Arovella Therapeutics Limited, a biotechnology company, focuses on the development of therapies for the treatment of cancer and conditions that affect the central nervous system in Australia and internationally. The company was formerly known as Suda Pharmaceuticals Ltd and changed its name to Arovella Therapeutics Limited in October 2021. Arovella Therapeutics Limited was incorporated in 1999 and is headquartered in Osborne Park, Australia.


Keywords: Biotechnology Cancer Life Sciences Treatment Of Cancer Otsuka Pharmaceutical

Home Page: www.arovella.com

ALA Technical Analysis

AIM Growth Series
,

Phone: 61 8 6142 5555


Officers

Name Title
Dr. Michael Baker CEO, MD & Director
Mr. Phillip Hains B Bus, C.A., CA, M.B.A., MBA Company Sec. & CFO
Mr. Stephen John Carter Consultant
Dr. Richard Franklin Project Director & Member of Scientific Advisory Board
Tony Macintyre GM & CTO

Exchange: AU

Country: AU : Australia

Currency: Australian Dollar (A$)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 2.3842
Price-to-Sales TTM: 56.1149
IPO Date:
Fiscal Year End: June
Full Time Employees: 0
Back to stocks